$74.39 Million in Sales Expected for Pacira Pharmaceuticals Inc (PCRX) This Quarter

Equities research analysts expect Pacira Pharmaceuticals Inc (NASDAQ:PCRX) to post sales of $74.39 million for the current quarter, according to Zacks. Five analysts have issued estimates for Pacira Pharmaceuticals’ earnings, with estimates ranging from $73.28 million to $75.11 million. Pacira Pharmaceuticals reported sales of $69.28 million in the same quarter last year, which indicates a positive year over year growth rate of 7.4%. The business is expected to announce its next earnings results on Thursday, May 3rd.

On average, analysts expect that Pacira Pharmaceuticals will report full year sales of $74.39 million for the current year, with estimates ranging from $309.08 million to $332.42 million. For the next year, analysts forecast that the business will post sales of $358.73 million per share, with estimates ranging from $337.58 million to $422.03 million. Zacks Investment Research’s sales averages are an average based on a survey of sell-side analysts that that provide coverage for Pacira Pharmaceuticals.

How to Become a New Pot Stock Millionaire

Pacira Pharmaceuticals (NASDAQ:PCRX) last released its quarterly earnings data on Wednesday, February 28th. The company reported $0.38 EPS for the quarter, beating analysts’ consensus estimates of ($0.08) by $0.46. Pacira Pharmaceuticals had a negative return on equity of 8.55% and a negative net margin of 14.87%. The firm had revenue of $79.08 million for the quarter, compared to analysts’ expectations of $79.06 million. During the same period in the prior year, the firm posted $0.09 earnings per share. The firm’s quarterly revenue was up 8.5% on a year-over-year basis.

PCRX has been the topic of a number of recent analyst reports. JPMorgan Chase & Co. reiterated a “hold” rating on shares of Pacira Pharmaceuticals in a report on Thursday, January 4th. BidaskClub cut Pacira Pharmaceuticals from a “buy” rating to a “hold” rating in a research note on Saturday, January 6th. ValuEngine cut Pacira Pharmaceuticals from a “hold” rating to a “sell” rating in a research note on Saturday, February 17th. Wedbush restated a “buy” rating and set a $80.00 price target on shares of Pacira Pharmaceuticals in a research note on Wednesday, December 20th. Finally, Zacks Investment Research cut Pacira Pharmaceuticals from a “hold” rating to a “sell” rating in a research note on Tuesday, January 9th. Three analysts have rated the stock with a sell rating, twelve have given a hold rating and eight have assigned a buy rating to the stock. The company currently has an average rating of “Hold” and an average price target of $44.06.

In other news, CEO David M. Stack sold 28,885 shares of the company’s stock in a transaction on Wednesday, January 10th. The stock was sold at an average price of $40.19, for a total transaction of $1,160,888.15. The transaction was disclosed in a document filed with the SEC, which is accessible through this link. 6.60% of the stock is currently owned by corporate insiders.

Several institutional investors have recently bought and sold shares of PCRX. First Republic Investment Management Inc. purchased a new stake in shares of Pacira Pharmaceuticals during the fourth quarter worth $201,000. Bouchey Financial Group Ltd purchased a new stake in shares of Pacira Pharmaceuticals during the fourth quarter worth $205,000. Twin Focus Capital Partners LLC purchased a new stake in shares of Pacira Pharmaceuticals during the fourth quarter worth $206,000. Redmile Group LLC purchased a new stake in shares of Pacira Pharmaceuticals during the fourth quarter worth $237,000. Finally, Fisher Asset Management LLC purchased a new stake in shares of Pacira Pharmaceuticals during the fourth quarter worth $241,000.

PCRX stock opened at $32.30 on Friday. Pacira Pharmaceuticals has a twelve month low of $27.80 and a twelve month high of $52.47. The company has a market capitalization of $1,302.78, a P/E ratio of -29.63 and a beta of 1.95. The company has a debt-to-equity ratio of 0.99, a current ratio of 6.96 and a quick ratio of 6.22.

TRADEMARK VIOLATION WARNING: This piece was originally published by Ticker Report and is owned by of Ticker Report. If you are viewing this piece on another site, it was illegally copied and republished in violation of US & international copyright law. The legal version of this piece can be read at https://www.tickerreport.com/banking-finance/3295576/74-39-million-in-sales-expected-for-pacira-pharmaceuticals-inc-pcrx-this-quarter.html.

Pacira Pharmaceuticals Company Profile

Pacira Pharmaceuticals, Inc is a holding company. The Company is a pharmaceutical company focused on the development, manufacture and commercialization of pharmaceutical products, based on its DepoFoam extended release drug delivery technology, for use primarily in hospitals and ambulatory surgery centers.

Get a free copy of the Zacks research report on Pacira Pharmaceuticals (PCRX)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for Pacira Pharmaceuticals (NASDAQ:PCRX)

Receive News & Ratings for Pacira Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Pacira Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.

Latest News

Evermay Wealth Management LLC Raises Stake in PepsiCo
Evermay Wealth Management LLC Raises Stake in PepsiCo
Financial Advocates Investment Management Buys Shares of 6,225 Oracle Co.
Financial Advocates Investment Management Buys Shares of 6,225 Oracle Co.
FTB Advisors Inc. Buys 3,606 Shares of Microsoft Co.
FTB Advisors Inc. Buys 3,606 Shares of Microsoft Co.
$1.56 Billion in Sales Expected for Post Holdings  This Quarter
$1.56 Billion in Sales Expected for Post Holdings This Quarter
Sierra Bancorp  Shares Bought by Geode Capital Management LLC
Sierra Bancorp Shares Bought by Geode Capital Management LLC
ArcBest  Rating Lowered to Hold at Zacks Investment Research
ArcBest Rating Lowered to Hold at Zacks Investment Research


© 2006-2018 Ticker Report. Google+.